Manu Chakravarthy

Manu Chakravarthy leads research & development and oversees the execution of all clinical related activities. Prior to Carmot, Dr. Chakravarthy served as Executive Vice President and Chief Medical Officer at Axcella Health, Inc. overseeing all phases of clinical development, regulatory affairs, quality, and scientific communications. Prior to Axcella, Dr. Chakravarthy served as the Vice President and Global Head of External R&D and Innovation Strategy in Diabetes and Cardiovascular Research at Eli Lilly. Before his global leadership role at Lilly, Dr. Chakravarthy was a Distinguished Scientist at Merck and worked across the R&D spectrum from discovery, clinical pharmacology, biomarker development, and late-stage drug development covering diverse disease areas. Dr. Chakravarthy received his MD from the University of Texas Houston Medical School and a Ph.D. in Cell Biology & Physiology from the MD Anderson Cancer Center and University of Texas Graduate School of Biomedical Sciences combined MD-PhD program. He trained in Internal Medicine at the Hospital of the University of Pennsylvania, and in Endocrinology, Diabetes, and Metabolism at Washington University School of Medicine in St. Louis. He is internationally recognized as a thought leader in metabolic diseases, reflected by his published work in numerous high-impact peer-reviewed scientific journals and invited speakership.